4[3]Primka EJ 3rd, Camisa C. Methotrexate - induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol, 1997, 36(5 Pt 2): 815 - 818.
5[5]Sprecher E, Bergman R, Sprecher H, et al. Reduced folate carrier (RFC - 1) gene expression in normal and psoriatic skin. Arch Dermatol Res, 1998, 290(12) :656- 660.
6[6]Jeffes EW 3rd, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth - inhibitory effects of methotrexate. J Invest Dermatol, 1995, 104(2): 183-188.
7[7]Jeffes EW 3rd, Lee GC, Said S, et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of pso riatic patients correlate with disease severity. J Invest Dermatol, 1995, 105(6): 733- 738.
8[8]Yamasaki E, Soma Y, Kawa Y, et al. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule - 1 and vascular cell adhesion molecule - 1 by cultured human umbilical vein endothelial cells. Br J Der matol, 2003, 149( 1 ): 30 - 38.
9[9]Piskin G, Heydendael VM, de Rie MA, et al. Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN - gamma and IL - 4 expression in psoriatic skin in situ. Arch Dermatol Res, 2003, 294(12) :559 - 562.
10[11]Jeffes EW 3rd, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth- inhibitory effects of methotrexate, J Invest Dermatol, 1995, 104(2): 183-188.
